Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Precision Medicine requires the cooperation of two major stakeholders with distinctly different businesses, Pharmaceutical and Diagnostics, working together to achieve the approval of drugs with diagnostics. Using specific case studies, this session will debate the often “opposing sides” of co-development, with the goal of maximizing communication, understanding and impact for future projects.
Session Chair Profile
M.D., Chief Executive Officer and President of GeneCentric Diagnostics
Dr. Lai-Goldman is the Chief Executive Officer and co-founder of GeneCentric Diagnostics, Inc., a molecular diagnostics company focused on developing and commercializing assays that enable oncologists and their patients to make informed, individualized, treatment decisions. She is also the managing partner of Personalized Science, LLC, a consulting company that is focused on innovative diagnostics for patients’ unmet clinical needs. Dr. Lai-Goldman currently serves on the board of directors of West Pharmaceutical Services, Inc., a provider of drug administration systems, and Qvella Corporation, a privately-held molecular diagnostics company. She is also a venture partner with Hatteras Venture Partners, a position she has held since August 2011. From 1990 to December 2008, Dr. Lai-Goldman served in various roles at Laboratory Corporation of America Holdings and its predecessor company, Roche Biomedical Laboratories, including Executive Vice President, Chief Medical Officer, and Chief Scientific Officer. Dr. Lai-Goldman received her medical degree from Columbia University College of Physicians and Surgeons.
Session Chair Profile
Ph.D., Senior Vice President, Genomic Medicine, Takeda Pharmaceutical Inc.
Dr. Eric Lai is SVP Genomic Medicine at Takeda Pharmaceutical. Before he joined Takeda, he was the SVP and Head of R&D at Gen-Probe (2009 – 2012) and before that he was the VP of Pharmacogenetics at GlaxoSmithKline for 13 years. Dr. Lai received his Ph.D., from Columbia University and did his post-doctoral training at Dr. Lee Hood’s laboratory at CalTech in the early days of the Human Genome Project. He was the co-scientific leader of The SNP Consortium and the Severe Adverse Reaction Consortium. For almost 20 years, Dr. Lai has focused his efforts in the clinical application of Pharmacogenomics in drug development and safety. In 2002, Dr. Lai discovered the association of HLA5701 to Abacavir hypersensitivity reaction and oversaw the clinical development and application of this test. The Abacavir HLA5701 discovery significantly improved the benefit-risk relationship by identifying patients at high risk for a serious drug adverse reaction and is frequently quoted in FDA guidance as one of the most important demonstrations of precision medicine.
Chief Commercial Officer and Executive Director, Premaitha Health PLC
Peter Collins is a pharmaceutical business development consultant to a number of Companies. Mr. Collins has a strong entrepreneurial background and has held senior executive roles, including CEO, at a number of early-stage diagnostics and life sciences companies. A seasoned executive in molecular diagnostics with a wealth of experience in strategic leadership, business development and commercialisation, he is currently Chief Business Officer at Premaitha Health. Mr. Collins previously served as VP, Head of Diagnostics at GlaxoSmithKline, where he led GSK’s Diagnostic Nucleus, supporting the diagnostic needs of Clinical Development Programs across all business units. Mr. Collins was formerly VP of Pharma Business Development for QIAGEN, driving the uptake of companion diagnostic programs in multiple partnerships across the pharma industry. Prior to its acquisition by QIAGEN, he was VP Business Development at DxS where he was pivotal in securing key companion diagnostic agreements for KRAS and EGFR. Peter previously served as VP of Marketing and Sales for Vysis Europe (now Abbott Molecular Diagnostics), and is a founder and board member of EPEMED, a European organization dedicated to advancing personalized medicine.